ANAB

NASD AnaptysBio, Inc.
Oct 21, 2026 · 6:38 PM ET LAST TRADE Market Closed

$47.89 ↓ -0.05 (-0.10%) Trading Down from the previous close of $47.94, $0.59 below the day’s high of $48.48

YTD change
-1.22%
vs 20-day SMA
-0.77%
vs 200-day SMA
-15.06%

Price ranges

Previous day
$44.02 $51.86
open $49.57 close $45.43
-$4.14 (-8.35%)
Today
$45.48 $48.48
open $45.48 now $47.89
+$2.41 (+5.30%)
Past week
$44.02 $51.86
from $45.59 now $47.89
+$2.30 (+5.04%)
Past month
$44.02 $53.93
from $53.92 now $47.89
-$6.03 (-11.18%)
This year
$42.00 $73.30
from $48.48 now $47.89
-$0.59 (-1.22%)

Price & Performance

-6.39 (-12.33%) / 6M

$43.48$52.91$62.33$71.76Apr 21Jul 22Oct 20

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral
  • The stock is 64.3% away from all-time highs of $134.00
  • ANAB is down 1% since the beginning of the year
  • ANAB is up 40% over the past 12 months
  • ANAB is down 11% over the past 1 month
  • 19% of all ANAB investors are betting against ANAB

ANAB reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is +33.2%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $5.11
Earnings momentum -500.7% Quarterly EPS growth
Quarterly change -500.7%

Valuation

P/E ratio N/A
Enterprise value $1.5B
Beta 2.14

Balance sheet & scale

Income$241.1K
Revenue$237.6M
Cash$164.1M
Debt$269.6K
Income / Debt 0.89×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $1.4B

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $438.94 +3.29%
MRNA Moderna, Inc. $242.08 +6.69%
RVMD Revolution Medicines, Inc. $196.55 +7.91%
ROIV Roivant Sciences Ltd. $34.92 +0.63%
BNTX BioNTech SE Sponsored ADR $91.17 +2.20%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.